Engineered immune cells take on tough leukemia in early trial
NCT ID NCT05350787
First seen Feb 19, 2026 · Last updated Jun 15, 2026 · Updated 17 times
Summary
This early-phase study tested a new CAR-T cell therapy called ThisCART19A in 10 adults with relapsed or hard-to-treat B-cell leukemia. The goal was to check safety and see how well the treatment worked. Participants received a single infusion of their own engineered immune cells, and researchers tracked side effects and cancer response for three months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.